Results 131 to 140 of about 67,273 (233)
Клиническая онкогематологияAIM. To compare the efficacy and toxicity of various regimens of autologous hematopoietic stem cell (HSC) mobilization (cytarabine + G-CSF, cyclophosphamide + G-CSF, and plerixafor + G-CSF) in hematologic malignancy patients with predicted poor HSC ...
Svetlana Sergeevna Elkhova +5 more
doaj +1 more source
European Journal of Haematology, Volume 116, Issue 6, Page 907-914, June 2026.ABSTRACT Introduction Allogeneic stem cell transplantation (allo‐SCT) and donor lymphocyte infusions (DLI) can elicit a graft‐versus‐leukemia (GvL) effect in pediatric patients with hematological malignancies. We report our single‐center experience with prophylactic DLI in high‐risk pediatric patients with leukemia or lymphoma, focusing on feasibility,
Denise Epple +8 more
wiley +1 more source
European Journal of Haematology, Volume 116, Issue 6, Page 771-784, June 2026.ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta +12 more
wiley +1 more source
Veterinary and Comparative Oncology, Volume 24, Issue 2, Page 382-392, June 2026.ABSTRACT Primary mediastinal lymphoma is rare in dogs and literature exploring this disease is limited. Therefore, the aim of this study was to describe presentation, treatment and outcome in a large cohort of dogs with mediastinal lymphoma and explore prognostic factors including chemotherapy protocol. This retrospective multi‐institute study included
Diogo Machado +11 more
wiley +1 more source
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma [PDF]
, 2020 al., et +7 more
core +1 more source
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy
Cancer, Volume 132, Issue 10, 15 May 2026.Abstract Background ASXL1 mutations (ASXL1MUT) are common in acute myeloid leukemia (AML) and have historically conferred an adverse prognosis with intensive chemotherapy. Given the increasing use of venetoclax (VEN)‐based lower intensity therapy (LIT), the European LeukemiaNet introduced a four‐gene genetic risk classifier in 2024 that categorizes ...
Jennifer Marvin‐Peek +26 more
wiley +1 more source
International Journal of Cancer, Volume 158, Issue 10, Page 2674-2683, 15 May 2026.What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Xue Tang +5 more
wiley +1 more source
Advanced Healthcare Materials, Volume 15, Issue 19, 22 May 2026.We developed a novel copper‐doped aluminum nano‐adjuvant (CuNA) to overcome cytarabine resistance in acute myeloid leukemia (AML). CuNA effectively sensitizes drug‐resistant AML cells to cytarabine by inducing mitochondrial dysfunction and inhibiting HMGCR/GPX4 to amplify ferroptosis.
Chao He +10 more
wiley +1 more source
Advanced Science, Volume 13, Issue 27, 13 May 2026.Schematic illustration of the synthesis protocol for Fe‐SH@Fn, an AML‐targeted nanoplatform engineered to co‐deliver shikonin (SH) and Fe3+, synergistically boosting antitumor immunity via ferroptosis induction and immunogenic cell death (ICD). ABSTRACT Acute myeloid leukemia (AML) remains a therapeutic challenge due to its low immunogenicity and ...
Shangqin Yang +9 more
wiley +1 more source
American Journal of Hematology, Volume 101, Issue 5, Page 949-960, May 2026.ABSTRACT The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC (n ...
Gaspar Aspas Requena +31 more
wiley +1 more source